Skip to main content
Clinical Trials/NCT06576050
NCT06576050
Active, not recruiting
Not Applicable

A Prospective Evaluation of Subjects Undergoing Weight Loss Surgery to Determine Cardiometabolic Responses to Exercise

Massachusetts General Hospital1 site in 1 country21 target enrollmentJanuary 25, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Massachusetts General Hospital
Enrollment
21
Locations
1
Primary Endpoint
Change in Peak VO2
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this study is to define how treatment of obesity impacts cardiometabolic performance during exercise in patients with established HFpEF or at risk for HFpEF. Multi-dimensional physical activity, including 6 minute walk distance, resting metabolic rate, the metabolic cost of initiating exercise, and low-level, intermediate, peak exercise, and recovery oxygen utilization patterns will be examined in relation to weight loss in people having bariatric surgery. We also aim to learn more about the relationship between obesity, exercise intolerance, and heart failure with preserved ejection fraction (HFpEF). We are interested in the extent to which HFpEF's manifestations are preventable or reversible with weight-loss interventions. The main questions it aims to answer are:

  1. How does weight loss surgery affect comprehensive measures of physical activity?
  2. What are the biochemical signatures of obesity and their reversibility in patients with HFpEF and obesity?

Detailed Description

A prospective evaluation of subjects with HFpEF or at risk for HFpEF undergoing laparoscopic sleeve gastrectomy surgery to determine cardiometabolic responses to exercise. We will prospectively evaluate twenty-one patients to determine cardiometabolic responses to exercise before and 12-months after bariatric surgery. We will map pulmonary/pulmonary vascular function, ventilatory efficiency (VE/VCO2 slope); left ventricular-systemic vascular function (based on echo measures) as well as exercise blood pressure responses (SBP at 30 Watts); sympathetic nervous system function during exercise will be assessed by heart rate-O2 pulse relationships; peripheral abnormalities characteristic of HFpEF will be measured by assessment of O2 kinetics during exercise onset and recovery. Additionally, global metabolic reserve will be captured by assessment of peak VO2. The comprehensive evaluation of these patients pre- and post-weight loss will further elucidate relationships between HFpEF and obesity, and their plasticity in response to weight loss, while also setting the stage to evaluate clinical trial endpoints that influence how patients function and feel (e.g. CPET-derived exercise capacity). We will also assess exercise capacity and additional markers of metabolic health.

Registry
clinicaltrials.gov
Start Date
January 25, 2022
End Date
November 1, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gregory D. Lewis, M.D.

Professor of Medicine

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for weight loss surgery (gastric sleeve procedure)
  • 40 years or older
  • PMH one or more of the following:
  • Diabetes Mellitus
  • Hypertension requiring medical treatment
  • Age \>65 years
  • History of HFpEF
  • Echocardiographic findings: left atrial enlargement (LAE), left ventricular hypertrophy (LVH), or right ventricular systolic pressure \>40 mmHg (RVSP)

Exclusion Criteria

  • Previous Bariatric surgery
  • Pregnancy
  • History of systolic heart failure, past or present LVEF of \<40%
  • Inability to perform exercise testing on a cycle ergometer (i.e. orthopedic conditions that preclude cycling or walking, recent systemic illness that compromises exercise capacity).
  • Any contraindication to performing exercise testing or any history of ventricular arrhythmia, any recent (within the last 3 months) or untreated supraventricular arrhythmia, elevated blood pressure at the time of presentation for exercise testing (\>155 mmHg systolic, or \>95 mmHg diastolic blood pressure), active or recent exacerbation of congestive heart failure, or history of reactive airways disease that is induced by exercise).
  • Acute myocardial infarction (3-5 days) or unstable angina
  • Uncontrolled symptomatic arrhythmias
  • Active endocarditis
  • Acute myocarditis or pericarditis
  • Symptomatic severe aortic stenosis

Outcomes

Primary Outcomes

Change in Peak VO2

Time Frame: baseline to month 12

To precisely quantify changes in peak oxygen uptake (peak VO2) achieved pre and post gastric sleeve surgery by performing cardiopulmonary exercise testing (CPET) at baseline (pre-surgery) and 12-months post-procedure (+/- 3 months). CPETs will be performed on a cycle ergometer.

Study Sites (1)

Loading locations...

Similar Trials